New Technology introduction; medical device
A MNC medical device company wanted to introduce Peritoneal Dialysis (PD) in parallel to their established In-Center Hemodialysis (ICHD), without interrupting their profitability. Regulatory approval, medical protocol approval and price approval were all needed from the National Health Service.
Successful HEOR analysis, and negotiation support demonstrated a saving of $177 million over 5 years for the National Health Service with the roll-out of PD
challenge
Secure government approval at profitable prices for both PD and ICHD. Demonstrate the improved patient outcome and the monetary saving for the National Health Service. Demonstrate to physicians the earnings from their use of both technologies
solution
Deploy multiple analytical methods and assist in negotiations with the National Health Service. Valuation methods included:
- Formulary and Protocol Optimization for in market utilization of both PD and ICHD
- Quantification of value of outcomes, diversion, avoidance and assessment demonstrating the benefit of side by side utility of both technologies
- Value based contracting support for insurance reimbursement payments
Community based disease model analysis and market intelligence demonstrating future utility of both technologies
results
- We demonstrated equivalent outcome & reduction in sequalae using PD and ICHD
- PD rose to gain 14% market share.
- The National Health Service approved our recommended valuation, pricing, protocol and deployment
- Protocol pricing generated profits for the client company and the physicians
- Patient satisfaction improved significantly with the new mobile technology
- With the two technologies in the marketplace, the client rose to market leadership
- The National Health Service saved more than 1.6% of its annual budget through
- diversion of patients to PD from ICHD
- reduction in sequalae expense due to improved patient compliance